CD33 and neoplasm: We next evaluated C-JUN impact on CAR T cells with different costimulation domains and observed that mice in the CD33 bbz-C-JUN and CD33 28z-C-JUN CAR T cell treatment groups had comparable effects in enhancing tumor control compared with non-C-JUN CAR T cells (Fig. 4M–O and Supplementary Fig. 6H).